NCT00210691View on ClinicalTrials.gov

A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

December 31, 1999

Study Completion Date

February 29, 2004

Conditions
Schizophrenia
Interventions
DRUG

Risperidone

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY